Literature DB >> 20195775

Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.

Emily P Slater1, Peter Langer, Volker Fendrich, Nils Habbe, Brunhilde Chaloupka, Elvira Matthäi, Mercedes Sina, Stephan A Hahn, Detlef K Bartsch.   

Abstract

Previous small scale studies reported that deleterious BRCA2 and CDKN2a germline mutations contribute to a subset of families with inherited pancreatic cancer. As the prevalence of those mutations in the setting of familial pancreatic cancer is still not well defined for the German population, we evaluated the presence of BRCA2 and CDKN2a germline mutations in a large cohort of familial pancreatic cancer (FPC) families from the German National Case Collection for Familial Pancreatic Cancer (FaPaCa). Fifty-six FPC families with at least two-first-degree relatives with confirmed pancreatic cancer that did not fulfill the criteria of other tumor predisposition syndromes, were analyzed for BRCA2 and CDKN2a germline mutations by DHPLC and/or direct sequencing. No deleterious CDKN2a mutations were identified in our families suggesting that CDKN2a mutations are unlikely to predispose PC in FPC families without melanoma. No deleterious BRCA2 mutations, but 6 unclassified variants, were detected in our FPC collection. Combining the prevalence of deleterious BRCA2 germline mutations from our previous separate study with the data from this study we were able to much more accurately estimate the BRCA2 carrier frequency for FPC families in the German population. A total of two mutations and 6 unclassified variants (mutation range: 2.8-11.4%) were thus identified in 70 German FPC families, indicating that the prevalence of BRCA2 mutations in the German FPC population is less frequent than previously reported.

Entities:  

Mesh:

Year:  2010        PMID: 20195775     DOI: 10.1007/s10689-010-9329-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  42 in total

1.  Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases.

Authors:  S E Applebaum; J A Kant; D C Whitcomb; I H Ellis
Journal:  Med Clin North Am       Date:  2000-05       Impact factor: 5.456

2.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

3.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Authors:  H F Vasen; N A Gruis; R R Frants; P A van Der Velden; E T Hille; W Bergman
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

4.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

5.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

6.  No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.

Authors:  Robert Grützmann; Christopher McFaul; Detlef K Bartsch; Mercedes Sina-Frey; Harald Rieder; Rainer Koch; Emma McCarthy; William Greenhalf; John P Neoptolemos; Hans Detlev Saeger; Christian Pilarsky
Journal:  Cancer Lett       Date:  2004-10-08       Impact factor: 8.679

7.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

Authors:  Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.

Authors:  Henry T Lynch; Pardeep Kaurah; Debrah Wirtzfeld; Wendy S Rubinstein; Scott Weissman; Jane F Lynch; William Grady; Sara Wiyrick; Janine Senz; David G Huntsman
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

9.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.

Authors:  P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch
Journal:  Gut       Date:  2009-05-25       Impact factor: 23.059

10.  German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families.

Authors:  H Rieder; M Sina-Frey; A Ziegler; S A Hahn; E Przypadlo; R Kress; B Gerdes; M Colombo Benkmann; T Eberl; R Grützmann; M Lörken; J Schmidt; D K Bartsch
Journal:  Onkologie       Date:  2002-06
View more
  23 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

Review 2.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

Review 4.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

Review 5.  Familial pancreatic cancer: challenging diagnostic approach and therapeutic management.

Authors:  Aikaterini Mastoraki; Victoria Chatzimavridou-Grigoriadou; Varvara Chatzipetrou; Sotiria Mastoraki; Ioannis S Papanikolaou; Nikolaos Danias; Vasilios Smyrniotis; Nikolaos Arkadopoulos
Journal:  J Gastrointest Cancer       Date:  2014-09

Review 6.  Diagnosis and management of pancreatic cancer.

Authors:  Zaheer S Kanji; Steven Gallinger
Journal:  CMAJ       Date:  2013-04-22       Impact factor: 8.262

Review 7.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Authors:  Ralph Schneider; Emily P Slater; Mercede Sina; Nils Habbe; Volker Fendrich; Elvira Matthäi; Peter Langer; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

9.  LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer.

Authors:  Emily P Slater; Volker Fendrich; Konstantin Strauch; Susanne Rospleszcz; Annette Ramaswamy; Elvira Mätthai; Brunhilde Chaloupka; Thomas M Gress; Peter Langer; Detlef K Bartsch
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

Review 10.  Progress report: familial pancreatic cancer.

Authors:  Ioannis Mintziras; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.